Targeted Oncology· @TargetedOnc · X·· 22 小时前评分70
正文 · 原文
One question I would ask the KEYNOTE-B49 investigators:
Did the PFS improvement translate into better symptom control, longer time to deterioration or improved quality of life?
When OS is neutral, patient-reported outcomes become especially important.
#ESMO26 #BreastCancer
54 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Targeted Oncology · x.com